Discover 1,068 paid clinical trials in Ogden, Utah. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,068
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
for
NASH With Fibrosis, MASH With Fibrosis
Location: Ogden UT, Sandy City UT, Englewood CO, Aurora CO,
Sponsor: Akero Therapeutics, Inc
Sex: All
Age: 18 - 70+
Code: NCT06215716
Phase3, Recruiting
Active & Responsive
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
for
Migraine
Location: Ogden UT, Aurora CO, Flagstaff AZ, Reno NV, Phoenix AZ,
Sponsor: Mayo Clinic
Sex: All
Age: 18 - 70
Code: NCT06972056
Recruiting
Active & Responsive
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
for
Cardiovascular Disease
Location: Layton UT, Meridian ID, Littleton CO,
Sponsor: Amgen
Sex: All
Age: 50 - 70+
Code: NCT07136012
Phase3, Recruiting
Active & Responsive
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
for
Depressive Disorder, Major
Location: Clinton UT, Las Vegas NV, Orange CA, Moorpark CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07412756
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
for
Alcohol Use Disorder
Location: Clinton UT, Denver CO, Scottsdale AZ, San Francisco CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07219966
Phase3, Recruiting
Active & Responsive
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
for
Psoriasis, Overweight or Obesity
Location: Layton UT, Reno NV, Phoenix AZ, Fremont CA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06857942
Recruiting
Active & Responsive
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
for
Sjögren, Sjogren Disease, Sjogren's Syndrome
Location: Salt Lake City UT, Plano TX, Webster TX, Memphis TN,
Sponsor: Cullinan Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT07041099
Phase1, Recruiting
Active & Responsive
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
for
Relapsed/Refractory Multiple Myeloma
Location: Salt Lake City UT, Aurora CO, Dallas TX, Milwaukee WI,
Sponsor: Caribou Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT05722418
Phase1, Recruiting
Active & Responsive
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Location: Salt Lake City UT, South Jordan UT, Bozeman MT,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07198074
Phase3, Recruiting
Active & Responsive
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Salt Lake City UT, Twin Falls ID, Boise ID, Meridian ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05136196
Phase2, Recruiting
Active & Responsive
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
for
Breast Cancer
Location: Salt Lake City UT
Sponsor: University of Utah
Sex: All
Age: 18+
Code: NCT06305312
Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Salt Lake City UT, Boise ID, Las Vegas NV, Reno NV,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06841354
Phase3, Recruiting
Active & Responsive
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
for
Ductal Carcinoma in Situ
Location: Salt Lake City UT, Walnut Creek CA, Duarte CA,
Sponsor: QuantumLeap Healthcare Collaborative
Sex: Female
Age: 18+
Code: NCT06075953
Phase2, Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Salt Lake City UT, Denver CO, Reno NV, Tucson AZ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase1, Recruiting
Active & Responsive
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
for
Non-Small Cell Lung Cancer, NSCLC,
Location: Salt Lake City UT, Duarte CA, Irvine CA,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT06043817
Phase1, Phase2, Recruiting
Active & Responsive
Improving Care for Rural Patients With Solid Tumors
for
Lung Cancer, Head and Neck Cancer, Thyroid Cancer,
Location: Salt Lake City UT, Grand Junction CO,
Sponsor: University of Colorado, Denver
Sex: All
Age: 18 - 70+
Code: NCT04916990
Recruiting
Active & Responsive
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
for
Polycythemia Vera
Location: Salt Lake City UT, Englewood CO, Redlands CA, Eugene OR,
Sponsor: Italfarmaco
Sex: All
Age: 18+
Code: NCT06093672
Phase3, Recruiting
Active & Responsive
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome